Roch Doliveux - UCB SA Insider

UCBJY -- USA Stock  

USD 38.45  0.000001  0.00%

Chairman of the Executive Committee, CEO, Executive Director

Dr. Roch Doliveux has served as NonExecutive Director of UCB S.A. since April 27, 2017. He served as Chairman of the Executive Committee, Chief Executive Officer, Executive Director of the Company between January 1, 2005 and December 31, 2014. He was Deputy Chairman of Executive Committee, Director General of the Pharma Sector of the Company between October 2003 and January 1, 2005. He is Doctor in Veterinarian Medicine from MaisonsAlfort, Mr. Doliveux is also Laureate of the Faculty of Medicine, Creteil, and holds a Masters of Business Administration from INSEAD or Institut Europeen dAdministration des Affaires, France with distinction. He joined the pharmaceutical industry early, first at CibaGeigy in Switzerland, in Peru and in France, and then at ScheringPlough Corporationrationration in various positions, including President of ScheringPlough International. Then, Roch Doliveux joined the Pierre Fabre group a Chief Executive Officer of Pierre Fabre Pharmaceuticals
Age: 60  Chairman Since 2017      
32 2 559 99 99  http://www.ucb.com
Doliveux joined UCB in October 2003 as Director General of the Pharma Sector and Deputy Chairman of the Executive Committee. He became CEO and Chairman of the Executive Committee of UCB on January 1, 2005. He is a member of the Board of Directors of UCB, Member of the Board of Stryker Corporationrationrationration in the United States, as well as a member of the Board of the European Federation of Pharmaceutical Association, the Innovative Medicines Initiative which is a publicprivate partnership between the European Union and EFPIA, WELBIO, the INSEAD International Council and Chairman of the Caring Entrepreneurship Fund .

Roch Doliveux Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 6.67 % which means that it generated profit of $6.67 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.73 % meaning that it generated $13.73 on every $100 dollars invested by stockholders.
The company has accumulated 1.82 B in total debt with debt to equity ratio (D/E) of 27.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.34 which is within standard range for the sector.

Similar Executives

Entity Summary

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA was founded in 1928 and is based in Brussels, Belgium. UCB SA operates under Biotechnology classification in USA and traded on OTC Market. It employs 7478 people.UCB SA (UCBJY) is traded on OTC Market in USA. It is located in All?e de la Recherche, 60 and employs 7,478 people.

UCB SA Leadership Team

Pascale Richetta, President
Detlef Thielgen, CFO
Kay Davies, Director
Dirk Teuwen, VP
Anna Richo, EVP
Viviane Monges, Director
Gerhard Mayr, Chairman
Cyril Janssen, Director
Cedric Rijckevorsel, Director, CFA
JeanChristophe Tellier, Chairman
Arnoud Calesberg, Director
Mark McDade, COO
Xavier Michel, President
Dhavalkumar Patel, President
Bharat Tewarie, President, MBA
Roch Doliveux, Chairman
Norman Ornstein, Director
Jeff Wren, President
JeanPierre Kinet, Director, Ph.D
Antje Witte, VP
Alice Dautry, Director
Harriet Edelman, Director, MBA
Ulf Wiinberg, Director
Thomas McKillop, Director, Ph.D
Charl Zyl, President
France Nivelle, VP
Fabrice Enderlin, President
Pierre Gurdjian, Director
Ismail Kola, EVP, Ph.D
Emmanuel Caeymaex, President
Evelyn Bergendal, Executive
Iris LoewFriedrich, President, Ph.D
CharlesAntoine Janssen, Director
Albrecht Graeve, Director
JeanLuc Fleurial, President
Alexander Moscho, President

Stock Performance Indicators

Current Sentiment - UCBJY

UCB SA Investor Sentiment
Macroaxis portfolio users are unemotional in their outlook on investing in UCB SA. What is your outlook on investing in UCB SA? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip
Also Currentnly Active
Purchased over 100 shares of
over a week ago
Traded for 10.44
Purchased over 300 shares of
over a week ago
Traded for 6.24
Purchased over 70 shares of
over a week ago
Traded for 23.42
Also please take a look at World Market Map. Please also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.